Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress
Agendia notes this study confirms findings from the STO-3 Trial, previously published in 2017 in JAMA Oncology, and continues to show that the use of MammaPrint to stratify patient populations could help prevent the overtreatment of breast cancer patients.